Merck and Moderna reported positive late-stage results for INTerpath-001, a Phase III trial evaluating Moderna’s bespoke mRNA therapeutic intismeran (mRNA-4157/V940) combined with Merck’s pembrolizumab versus pembrolizumab alone in Stage IIB–IV cutaneous melanoma. The companies said the combination improved clinical outcomes, and the study crossed a key milestone after the trial’s design allowed early completion signals based on toxicity. This is being positioned as a potential landmark for mRNA therapeutics in oncology beyond vaccines, with the trial offering a rare confirmation at Phase III that personalized mRNA immunotherapy can translate into measurable benefit. Regulatory and competitive implications hinge on the magnitude and consistency of response and survival endpoints, along with how durable the benefit is across biomarker-defined subgroups. Additional scrutiny will likely focus on manufacturing feasibility and controls that accompany bespoke therapeutics.